|Videos|July 7, 2023

KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC

Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.


Latest CME